nad+ vs klow Foundation Stack 02 – WhyNot Labs NAD Therapy: Microdosing vs. Loading

doi: 10.1016/S0015-3796(17)30412-2 52 PaulS.DuttaR.GhoshA.BanerjeeA.BhattacharyaS.TalukdarP.et al

10.3390/nu9060622 59 JoH.BritoS.KwakB

It is plausible that the lack of ergogenic effects could be attributed to the trained participant cohort in the cycling studies (VO 2peak range = 56.3 58.1 ml.kg 1 .min 1 ), such that a recent point-counterpoint debate suggests due to an elevated NO at baseline compared to their untrained counterparts this could blunt the ergogenic effect (Hultstrm et al

V.AdyaA

In 17% of patients in the CDDP + GSH group (P = 0.38)

Injectable administration, specifically subcutaneous (just under the skin), bypasses the digestive system entirely